4,661 AbbVie Inc. $ABBV Shares Sold by American National Bank & Trust

American National Bank & Trust cut its stake in AbbVie Inc. (NYSE:ABBV) by 6.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 72,406 shares of the company’s stock after selling 4,661 shares during the period. AbbVie accounts for approximately 1.7% of American National Bank & Trust’s portfolio, making the stock its 16th largest position. American National Bank & Trust’s holdings in AbbVie were worth $18,941,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in ABBV. State Street Corp boosted its stake in AbbVie by 1.7% during the second quarter. State Street Corp now owns 82,596,748 shares of the company’s stock worth $20,784,646,000 after acquiring an additional 1,379,232 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in AbbVie by 0.7% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock valued at $3,590,323,000 after purchasing an additional 106,091 shares during the last quarter. Legal & General Group Plc purchased a new position in AbbVie in the second quarter worth about $2,905,952,000. Deutsche Bank AG lifted its stake in shares of AbbVie by 13.0% in the second quarter. Deutsche Bank AG now owns 10,772,949 shares of the company’s stock worth $2,710,905,000 after buying an additional 1,241,587 shares in the last quarter. Finally, Amundi increased its position in shares of AbbVie by 2.4% during the first quarter. Amundi now owns 10,698,095 shares of the company’s stock valued at $2,326,728,000 after acquiring an additional 247,689 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Insider Transactions at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.06% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. Bank of America reaffirmed a “buy” rating on shares of AbbVie in a research report on Tuesday, September 8th. Canaccord Genuity Group upped their price objective on AbbVie from $282.00 to $290.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. Barclays raised their price objective on shares of AbbVie from $275.00 to $300.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. BMO Capital Markets boosted their price objective on shares of AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Finally, Weiss Ratings upgraded AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $274.32.

AbbVie Price Performance

Shares of ABBV stock traded up $7.09 during trading hours on Wednesday, hitting $273.78. The stock had a trading volume of 1,927,853 shares, compared to its average volume of 6,412,232. The stock has a market capitalization of $483.72 billion, a price-to-earnings ratio of 77.34, a PEG ratio of 1.20 and a beta of 0.24. The stock’s 50-day moving average price is $258.12 and its two-hundred day moving average price is $235.42. AbbVie Inc. has a one year low of $190.75 and a one year high of $274.94.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. During the same quarter in the prior year, the firm earned $2.97 earnings per share. AbbVie’s revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities research analysts predict that AbbVie Inc. will post 14.05 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a dividend of $1.73 per share. The ex-dividend date is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.5%. AbbVie’s dividend payout ratio (DPR) is presently 195.48%.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie and Genmab reported that Epkinly (epcoritamab) plus R-CHOP reduced the risk of disease progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma (DLBCL). The Phase 3 trial met its progression-free-survival goal and could support regulatory filings and a larger role for Epkinly in frontline treatment, potentially challenging Roche’s Polivy. AbbVie and Genmab Epkinly DLBCL results
• Positive Sentiment: The FDA granted two Breakthrough Therapy Designations to AbbVie’s investigational antibody-drug conjugate telisotuzumab adizutecan (Temab-A or ABBV-400) for colorectal cancer and non-small cell lung cancer. The designations strengthen AbbVie’s oncology pipeline, although the drug remains investigational and commercial success is not assured. AbbVie Temab-A Breakthrough Therapy Designations
• Positive Sentiment: Scotiabank raised its AbbVie price target from $280 to $320 and maintained a “sector outperform” rating, adding to bullish Wall Street sentiment. Analysts cited AbbVie’s pipeline and growth prospects as reasons for further upside. Scotiabank raises AbbVie price target
• Neutral Sentiment: AbbVie is scheduled to report third-quarter results later in October, making upcoming earnings, guidance and pipeline commentary potential near-term catalysts. AbbVie upcoming third-quarter earnings
• Negative Sentiment: AbbVie updated third-quarter adjusted EPS guidance to $3.73-$3.77 after recording $216 million in acquired in-process research and development and milestone expenses. The expense reduced full-year adjusted EPS guidance by $0.11 and places the quarterly range below the cited consensus estimate of $3.85. AbbVie updates 2026 EPS guidance
• Negative Sentiment: Some coverage highlights AbbVie’s elevated reported payout ratio, estimated at roughly 190%, raising questions about dividend coverage. However, this measure can be distorted by accounting items and should be assessed alongside cash flow, adjusted earnings and the company’s strong recent revenue growth. AbbVie dividend payout analysis

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.